Your browser doesn't support javascript.
loading
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group.
Damaschin, Carla; Goergen, Helen; Kreissl, Stefanie; Plütschow, Annette; Breywisch, Frank; Mathas, Stephan; Meissner, Julia; Sökler, Martin; Topp, Max S; Vucinic, Vladan; Zimmermann, Andreas; von Tresckow, Bastian; Fuchs, Michael; Engert, Andreas; Borchmann, Peter; Eichenauer, Dennis A.
Afiliación
  • Damaschin C; First Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany.
  • Goergen H; German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.
  • Kreissl S; First Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany.
  • Plütschow A; German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.
  • Breywisch F; First Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany.
  • Mathas S; German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.
  • Meissner J; First Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany.
  • Sökler M; German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.
  • Topp MS; Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany.
  • Vucinic V; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Max-Delbrück-Center for Molecular Medicine, Berlin, and Experimental and Clinical Research Center (ECRC), Berlin, Germany.
  • Zimmermann A; Fifth Department of Internal Medicine, University Hospital Heidelberg, Heidelberg, Germany.
  • von Tresckow B; Second Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.
  • Fuchs M; Second Department of Internal Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Engert A; Department of Hematology and Cell Therapy, Medical Oncology, Hemostaseology, University Hospital Leipzig, Leipzig, Germany.
  • Borchmann P; Department of Internal Medicine III, University Hospital Munich, Munich, Germany.
  • Eichenauer DA; German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.
Leukemia ; 36(2): 580-582, 2022 02.
Article en En | MEDLINE | ID: mdl-34408266

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Ensayos Clínicos Controlados Aleatorios como Asunto / Neoplasias Primarias Secundarias / Ensayos Clínicos Fase II como Asunto / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Ensayos Clínicos Controlados Aleatorios como Asunto / Neoplasias Primarias Secundarias / Ensayos Clínicos Fase II como Asunto / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido